Veterans' Pain Care Organizational Improvement Comparative Effectiveness Study
CompletedPhase 2NCT03026790
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
Background and significance: Treatment with opioid pain medications (like hydrocodone and morphine) is common for severe pain, but studies show these medications may not always help and can cause serious problems. High daily doses of opioids can be especially unsafe. To help patients with chronic pain have better quality of life and avoid medication toxicity, health care teams need to manage pain while helping patients reduce opioid medication doses to safer levels.
Study details
- Official title
- Comparative Effectiveness of Patient-Centered Strategies to Improve Pain Management and Opioid Safety for Veterans
- Conditions
- Interventions
- Other: Medication management
- Other: Non-pharmacological pain management
- Drug: Buprenorphine-Naloxone
- Sponsor
- University of Minnesota
- Collaborators
- Patient-Centered Outcomes Research Institute
- Start date
- 2017-10-19
- Primary completion
- 2022-03-17
- Sex
- All
- Age range
- from 21 Years
- Results posted
- Yes, on ClinicalTrials.gov
- Countries
- United States
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Moderate or high-dose long-term opioid therapy (≥ 20 ME mg daily for at least 3 months) for chronic pain * Chronic pain of at least moderate severity (defined as pain that is present every or nearly every day for ≥ 6 months and with a score on the PEG 3-item pain measure of ≥ 5) Exclusion Criteria: * Dementia diagnosis * Unstable or severe untreated psychiatric disorder, including severe untreated substance use disorder or active suicidal ideation * Unstable or end-stage medical disease that would interfere with participation, including cancer requiring active treatment and life expectancy \< 12 months * Documentation of suspected controlled substance diversion * Inability to communicate by telephone
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT03026790